Amniotic fluid embolism pathophysiology suggests the new diagnostic armamentarium: β-tryptase and complement fractions C3-C4 are the indispensable working tools

International Journal of Molecular Sciences

Volumn 16, Issue 3, 2015, Pages 6557-6570

  Paolo Busardò, Francesco ^a   Frati, Paola ^a,b   Zaami, Simona ^a   Fineschi, Vittorio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Amniotic fluid embolism; Complement; Immune response; Immunohistochemistry; Mast cell degranulation

Indexed keywords

ACTIVIN A; BLOOD CLOTTING FACTOR 12; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ENDOTHELIN; FETAL ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; PROOPIOMELANOCORTIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 1; SQUAMOUS CELL CARCINOMA ANTIGEN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

AMNION FLUID EMBOLISM; ANAPHYLAXIS; ARMAMENTARIUM; BLOOD CLOTTING DISORDER; CELL ACTIVATION; COMA; CONFOCAL LASER MICROSCOPY; HEART ARREST; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAST CELL; MAST CELL DEGRANULATION; REVIEW; SEIZURE; SEPTIC SHOCK; SEROLOGY; SURGICAL TECHNIQUE; ANIMAL; FEMALE; METABOLISM; PATHOPHYSIOLOGY; PREGNANCY;

SCOPUS;

ANIMALS; COMPLEMENT C3; COMPLEMENT C4; EMBOLISM, AMNIOTIC FLUID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAST CELLS; PREGNANCY; TRYPTASES;

EID: 84925871458     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16036557     Document Type: Review

References (62)

1. Kramer, M.S.; Rouleau, J.; Liu, S.; Bartholomew, S.; Joseph, K.S. Maternal Health Study Group of the Canadian Perinatal Surveillance System. Amniotic fluid embolism: Incidence, risk factors, and impact on perinatal outcome. BJOG 2012, 119, 874–879.
2. Clark, S.L. Amniotic fluid embolism. Obstet. Gynecol. 2014, 123, 337–348.
3. Frati, P.; Foldes Papp, Z.; Zaami, S.; Busardò, F.P. Amniotic fluid embolism: What level of scientific evidence can be drawn? A systematic review. Curr. Pharm. Biotechnol. 2014, 14, 1157–1162.
4. Clark, S.L.; Hankins, G.D.V.; Dudley, D.A.; Dildy, G.A.; Porter, T.F. Amniotic fluid embolism: Analysis of the national registry. Am. J. Obstet. Gynecol. 1995, 172, 1158–1169.
5. Conde-Agudelo, A.; Romero, R. Amniotic fluid embolism: An evidence-based review. Am. J. Obstet. Gynecol. 2009, 201, 445e1–445e13.
6. Busardò, F.P.; Frati, P.; Karch, S.B.; Fineschi, V. Epidemiological and clinical data of amniotic fluid embolism in forensic settings. Curr. Pharm. Biotechnol. 2014, 14, 1189–1194.
7. Homson, A.J.; Greer, I.A. Non-haemorrhagic obstetric shock. Best Pract. Res. Clin. Obstet. Gynaecol. 2000, 14, 19–41.
8. Attwood, M.D. Fatal pulmonary embolism by amniotic fluid. J. Clin. Pathol. 1956, 9, 38–46.
9. Jacob, H.S.; Hammerschmidt, D.H. Tissue damage caused by activated complement and granulocytes in shock lung, post perfusion lung, and after amniotic fluid embolism: Ramifications for therapy. Ann. Chir. Gynaecol. 1982, 71, 3–9.
10. Luskin, A.T.; Luskin, S.S. Anaphylaxis and anaphylactoid reactions: Diagnosis and management. Am. J. Ther. 1996, 3, 515–520.
11. Payne, V.; Kam, P.C. Mast cell tryptase: A review of its physiology and clinical significance. Anaesthesia 2004, 59, 695–703.
12. Fineschi, V.; Riezzo, I.; Cantatore, S.; Pomara, C.; Turillazzi, E.; Neri, M. Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism. Virchows Arch. 2009, 454, 283–290.
13. Nishio, H.; Matsui, K.; Miyazaki, T.; Tamura, A.; Iwata, M.; Suzuki, K. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Sci. Int. 2002, 126, 53–56.
14. Edston, E.; Eriksson, O.; van Hage, M. Mast cell tryptase in postmortem serum-reference values and confounders. Int. J. Leg. Med. 2007, 121, 275–280.
15. Mayer, D.E.; Krauskopf, A.; Hemmer, W.; Moritz, K.; Jarisch, R.; Reiter, C. Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci. Int. 2011, 212, 96–101.
16. Farrar, S.C.; Gherman, R.B. Serum tryptase analysis in a woman with amniotic fluid embolism: A case report. J. Reprod. Med. 2001, 46, 926–928.
17. Benson, M.D.; Kobayashi, H.; Silver, R.K.; Oi, H.; Greenberger, P.A.; Terao, T. Immunologic studies in presumed amniotic fluid embolism. Obstet. Gynecol. 2001, 97, 510–514.
18. Fineschi, V.; Gambassi, R.; Gherardi, M.; Turillazzi, E. The diagnosis of amniotic fluid embolism: An immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int. J. Leg. Med. 1998, 111, 238–243.
19. Hammerschmidt, D.E.; Ogburn, P.L.; Williams, J.E. Amniotic fluid activates complement: A role in amniotic fluid embolism syndrome? J. Lab. Clin. Med. 1984, 104, 901–907.
20. Oi, H.; Kobayashi, H.; Hirashima, Y.; Yamazaki, T.; Kobayashi, T.; Terao, T. Serological and immunohistochemical diagnosis of amniotic fluid embolism. Semin. Thromb. Hemost. 1998, 24, 479–448.
21. Kobayashi, H.; Ohi, H.; Terao, T. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc α 2–6GalNAc. Am. J. Obstet. Gynecol.1993, 168, 848–853.
22. Hikiji, W.; Tamura, N.; Shigeta, A.; Kanayama, N.; Fukunaga, T. Fatal amniotic fluid embolism with typical pathohistological, histochemical and clinical features. Forensic Sci. Int. 2013, 226, e16–e19.
23. Toro, K.; Borka, K.; Kardos, M.; Kristof, I.; Sotonyi, P. Expression and function of C5a receptor in a fatal anaphylaxis after honey bee sting. J. Forensic Sci. 2011, 56, 526–528.
24. Tamura, N.; Kimura, S.; Farhana, M.; Uchida, T.; Suzuki, K.; Sugihara, K.; Itoh, H.; Ikeda, T.; Kanayama, N. C1 esterase inhibitor activity in amniotic fluid embolism. Crit. Care Med. 2014, 42, 1392–1396.
25. Ito, F.; Akasaka, J.; Koike, N.; Uekuri, C.; Shigemitsu, A.; Kobayashi, H. Incidence, diagnosis and pathophysiology of amniotic fluid embolism. J. Obstet. Gynaecol. 2014, 34, 580–584.
26. Benson, M.D.; Kobayashi, H.; Sehgal, L.R.; Oi, H.; Haney, E.I. Complement, fetal antigen, and shaking rigors in parturients. J. Matern. Fetal Neonatal Med. 2006, 19, 31–34.
27. Benson, M.D. A hypothesis regarding complement activation and amniotic fluid embolism. Med. Hypotheses 2007, 68, 1019–1025.
28. Tosi, M. Molecular genetics of C1 inhibitor. Immunobiology 1998, 199, 358–365.
29. Han, E.D.; Mac Farlane, R.C.; Mulligan, A.N.; Scafidi, J.; Davis, A.E., III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Investig. 2002, 109, 1057–1063.
30. Cugno, M.; Cicardi, M.; Bottasso, B.; Coppola, R.; Paonessa, R.; Mannucci, P.M.; Agostoni, A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997, 89, 3213–3218.
31. Schmaier, A.H.; Murray, S.C.; Heda, G.D.; Farber, A.; Kuo, A.; Mc Crae, K.; Cines, D.B. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J. Biol. Chem. 1989, 264, 18173–18179.
32. Schmaier, A.H. The elusive physiologic role of factor XII. J. Clin. Investig. 2008, 118, 3006–3009.
33. Landesman, R.; Campbell, W.L.; Wilson, K. Uterine relaxant properties of bradykinin in vitro. Nature 1963, 197, 1208–1209.
34. Spencer-Gregson, R.N. Uterine hypotonia. Br. Med. J. 1971, 4, doi:10.1136/bmj.4.5782.301.
35. Tanaka, A.; Suzuki, Y.; Sugihara, K.; Kanayama, N.; Urano, T. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in vitro. Life Sci. 2009, 85, 220–225.
36. Horn, K.D.; Halsey, J.F.; Zumwalt, R.E. Utilization of serum tryptase and immunoglobulin e assay in the postmortem diagnosis of anaphylaxis. Am. J. Forensic Med. Pathol. 2004, 25, 37–43.
37. Ansari, M.Q.; Zamora, J.L.; Lipscomb, M.F. Postmortem diagnosis of acute anaphylaxis by serum tryptase analysis. Am. J. Clin. Pathol. 1993, 9, 101–103.
38. Benson, M.D. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin. Dev. Immunol. 2012, 2012, doi:10.1155/2012/946576.
39. Erdei, A.; Andrásfalvy, M.; Péterfy, H.; Tóth, G.; Pecht, I. Regulation of mast cell activation by complement-derived peptides. Immunol. Lett. 2004, 29, 39–42.
40. Rat, W.H.; Hoferr, S.; Sinicina, I. Amniotic fluid embolism: An interdisciplinary challenge: Epidemiology, diagnosis and treatment. Dtsch. Arztebl. Int. 2014, 111, 126–132.
41. Turillazzi, E.; Neri, M.; Bello, S.; Riezzo, I.; Fineschi, V. Amniotic fluid embolism: Moving diagnosis through the time: From the mechanical pulmonary vascular occlusion until an immune-inflammatory pathogenesis? Curr. Pharm. Biotechnol. 2014, 14, 1179–1188.
42. Stawicki, S.P.; Papadimos, T.J. Challenges in managing amniotic fluid embolism: An up-to-date perspective on diagnostic testing with focus on novel biomarkers and avenues for future research. Curr. Pharm. Biotechnol. 2014, 14, 1168–1178.
43. Kanayama, N.; Yamazaki, T.; Naruse, H.; Sumimoto, K.; Horiuchi, K.; Terao, T. Determining zinc coproporphyrin in maternal plasma—A new method for diagnosing amniotic-fluid embolism. Clin. Chem. 1992, 38, 526–529.
44. Hosono, K.; Matsumura, N.; Matsuda, N.; Fujiwara, H.; Sato, Y.; Konishi, I. Successful recovery from delayed amniotic fluid embolism with prolonged cardiac resuscitation. J. Obstet. Gynaecol. Res. 2011, 37, 1122–1125.
45. Takeshima, N.; Suminami, Y.; Takeda, O.; Abe, H.; Kato, H. Origin of CA125 and SCC antigen in human amniotic fluid. Asia Ocean. J. Obstet. Gynaecol. 1993, 19, 199–204.
46. Usta, I.M.; Sibai, B.M.; Mercer, B.M.; Kreamer, B.L.; Gourley, G.R. Use of maternal plasma level of zinc-coproporphyrin in the prediction of intrauterine passage of meconium: A pilot study. J. Matern. Fetal Neonatal Med. 2000, 9, 201–213.
47. Oi, H.; Naruse, K.; Noguchi, T.; Sado, T.; Kimura, S.; Kanayama, N.; Terao, T.; Kobayashi, H. Fatal factors of clinical manifestationsand laboratory testing in patients with amniotic fluid embolism. Gynecol. Obstet. Investig. 2010, 70, 138–144.
48. Abboud, J.; Murad, Y.; Chen-Scarabelli, C.; Saravolatz, L.; Scarabelli, T.M. Peripartum cardiomyopathy: A comprehensive review. Int. J. Cardiol. 2007, 118, 295–303.
49. Smulian, J.C.; Vintzileos, A.M.; Lai, Y.L.; Santiago, J.; Shen-Schwarz, S.; Campbell, W.A. Maternal chorioamnionitis and umbilical vein interleukin-6 levels for identifying early neonatalsepsis. J. Matern. Fetal Neonatal Med. 1999, 8, 88–94.
50. Khosravi, J.; Krishna, R.G.; Bodani, U.; Diamandi, A.; Khaja, N.; Kalra, B.; Kumar, A. Immunoassay of serine-phosphorylatedisoform of insulin-like growth factor (IGF) binding protein(IGFBP)-1. Clin. Biochem. 2007, 40, 86–93.
51. Van Cortenbosch, B.; Huel, C.; HoufflinDebarge, V.; Luton, D.; Lambaudie, E.; Porquet, D.; Guibourdenche, J. Biologic tests forthe diagnosis of amniotic fluid embolism. Ann. Biol. Clin. (Paris) 2007, 65, 153–160.
52. Florio, P.; Cobellis, L.; Luisi, S.; Ciarmela, P.; Mseveri, F.; Bocchi, C.; Petraglia, F. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol. Cell. Endocrinol. 2001, 180, 123–130.
53. Florio, P.; Lambert-Messerlian, G.; Severi, F.M.; Buonocore, G.; Canick, J.A.; Petraglia, F. Fetal neural tube defects: Maternal serum and amniotic fluid activin A levels. Prenat. Diagn. 2004, 24, 574–575.
54. De Lemos, J.A.; Morrow, D.A. Brain natriuretic peptide measurement in acute coronary syndromes: Ready for clinical application? Circulation 2002, 106, 2868–2870.
55. Lev-Sagie, A.; Bar-Oz, B.; Salpeter, L.; Hochner-Celnikier, D.; Arad, I.; Nir, A. Plasma concentrations of N-terminal pro-B-type natriuretic peptide in pregnant women near labor andduring early puerperium. Clin. Chem. 2005, 51, 1909–1910.
56. Syversen, U.; Opsjon, S.L.; Stridsberg, M.; Sandvik, A.K.; Dimaline, R.; Tingulstad, S.; Arntzen, K.J.; Brenna, E.; Waldum, H.L. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. J. Clin. Endocrinol. MeTable 1996, 81, 4470–4475.
57. Sarandakou, A.; Kontoravdis, A.; Kontogeorgi, Z.; Rizos, D.; Phocas, I. Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 1992, 44, 215–220.
58. Kauppila, S.; Tekay, A.; Risteli, L.; Koivisto, M.; Risteli, J. Type I and type III procollagenpropeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesisimperfecta. Eur. J. Clin. Investig. 1998, 28, 831–837.
59. Mock, P.; Frydman, R.; Bellet, D.; Chassin, D.; Bischof, P.; Campana, A.; Bidart, J.M. Expression of pro-EPIL peptides encoded by the insulin-like 4 (INSL4) gene in chromosomally abnormal pregnancies. J. Clin. Endocrinol. Metable 2000, 85, 3941–3944.
60. Sarandakou, A.; Malamitsi-Puchner, A.; Protonotariou, E.; Rigopoulou, U.; Papagianni, B.; Creatsas, G. Indicative markers of cell proliferation and apoptosis during the perinatal period. Am. J. Perinatol. 2003, 20, 283–288.
61. Legrand, M.; Rossignol, M.; Dreux, S.; Luton, D.; Ventré, C.; Barranger, E.; Laribi, S.; Payen, D.; Muller, F. Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism. Crit. Care Med. 2012, 40, 2059–2063.
62. Busardò, F.P.; Gulino, M.; di Luca, N.M.; Montanari Vergallo, G.; Pacchiarottti, A.; Frati, P. Not only a clinical nightmare: Amniotic fluid embolism in court. Curr. Pharm. Biotechnol. 2014, 14, 1195–2000.